Daclizumab
As of the edition of 20 October 2026, Daclizumab is an antibody: withdrawn from the market in 2018; acts on IL2RA; US protection ended in 2009.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2018
- Kind
- Antibody
- Brand name
- Zenapax
- First approved
- 10 December 1997 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Biogen; 2 holders in all
- Withdrawn from market
- 27 March 2018 (in some regions)
- Registered trials
- 60, 7 stopped early
- Disease areas
- Immune system; Hormones; Nutrition and metabolism; Blood and lymph; Eye; Nervous system
US protection
US protection ended in 2009.
US protection ended in 2009, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Roche. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Daclizumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL2RA | Interleukin-2 receptor subunit alpha | P01589 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 33 | 29 | 0 | 4 |
| Phase 3 | 11 | 9 | 0 | 2 |
| Phase 4 | 10 | 9 | 0 | 0 |
| All trials | 60 |